Lakefront Biotherapeutics (LKFT) Non Operating Income (2017 - 2018)

Lakefront Biotherapeutics (LKFT) has reported Non Operating Income for 8 consecutive years, with $4.5 million the latest figure, recorded in Q4 2024.

• In Q4 2024, Non Operating Income changed N/A year-over-year to $4.5 million; the TTM figure through Dec 2024 stood at -$57.1 million (changed N/A YoY), while the FY2024 annual figure was $4.5 million, up 734.27% from the prior year.
• Non Operating Income advanced to $4.5 million in Q4 2024 per LKFT's latest filing, from -$138.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $60.3 million in Q3 2022 and bottomed at -$138.0 million in Q4 2022.
• Historically, Non Operating Income has averaged -$18.9 million across 4 years, with a median of $4.5 million in 2024.
• Annual changes were most pronounced in 2020 — Non Operating Income plunged 1086.57% — and 2022, when it surged 273.2%.
• Lakefront Biotherapeutics' Non Operating Income stood at -$37.6 million in 2020, then jumped by 142.97% to $16.2 million in 2021, then slumped by 954.4% to -$138.0 million in 2022, then jumped by 103.25% to $4.5 million in 2024.
• Business Quant data shows LKFT's Non Operating Income at $4.5 million in Q4 2024, -$138.0 million in Q4 2022, and $60.3 million in Q3 2022.